+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07652762

Safety and Preliminary Effectiveness Study of IN10018 Combined with Dalpiciclib for Adults with Progressive Meningiomas

Led by Capital Medical University · Updated on 2026-10-21

24

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and preliminary effectiveness of a combination treatment using IN10018 and dalpiciclib in adults with progressive meningiomas. These tumors arise from the membranes around the brain and have continued to grow or returned after earlier treatments. This open-label Phase Ib study aims to find the recommended dose of the combination and assess its impact on tumor growth and related biomarkers. Participants will take both IN10018 and dalpiciclib by mouth in 28-day treatment cycles. Each drug is taken once daily for 21 days followed by 7 days off. The study has two phases a dose-confirmation phase to determine the best dose using a modified 33 design, and a dose-expansion phase where participants receive the recommended dose. Treatment continues until tumor progression, unacceptable side effects, or other reasons to stop. During the study, researchers will monitor side effects throughout treatment and for up to 30 days after the last dose, for about 24 months. They will also assess tumor response, progression-free survival, overall survival, and other measures over up to 36 months. Participants will have laboratory tests and evaluations to check organ function, tumor size, and treatment effects. The total study duration includes treatment and follow-up periods extending several years.

CONDITIONS

Brief Title

IN10018 in Combination With Dalpiciclib for Progressive Meningiomas

Research Team

R

Research Secretary

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here